CVE:ACST Acasti Pharma (ACST) Stock Price, News & Analysis C$0.58 +0.01 (+1.75%) As of 03/27/2023 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Acasti Pharma Stock (CVE:ACST) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Acasti Pharma alerts:Sign Up Key Stats Today's RangeC$0.56▼C$0.5850-Day RangeC$0.58▼C$0.5852-Week RangeC$0.47▼C$1.66Volume2,450 shsAverage Volume6,576 shsMarket CapitalizationC$18.19 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAcasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.Read More… Receive ACST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acasti Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address ACST Stock News HeadlinesOTC Markets Hosts Virtual Investor Presentation with Prashant Kohli, CEO of Grace Therapeutics (Acasti Pharma), with John Vandermosten, Senior Analyst at Zacks SCROctober 29, 2024 | msn.comLife Sciences Virtual Investor Forum Agenda Announced for September 19thSeptember 16, 2024 | finance.yahoo.comJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are already using to their advantage… It allows them to treat this new asset like actual cash.May 28, 2025 | Premier Gold Co (Ad)ACST Stock Earnings: Acasti Pharma Beats EPS for Q1 2025August 9, 2024 | markets.businessinsider.comAcasti Pharma Inc. (ACST)April 6, 2024 | finance.yahoo.comAcasti Pharma Inc. Class AMarch 14, 2024 | edition.cnn.comAcasti Pharma (ACST) Price Target Increased by 200.00% to 6.12February 25, 2024 | msn.comAcasti Announces Third Fiscal Quarter 2024 Financial Results and Business HighlightsFebruary 12, 2024 | finance.yahoo.comSee More Headlines ACST Stock Analysis - Frequently Asked Questions How have ACST shares performed this year? Acasti Pharma's stock was trading at C$0.58 at the beginning of the year. Since then, ACST stock has increased by 0.0% and is now trading at C$0.58. View the best growth stocks for 2025 here. How do I buy shares of Acasti Pharma? Shares of ACST stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Acasti Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Acasti Pharma investors own include Genius Brands International (GNUS), Tesla (TSLA), Workhorse Group (WKHS), Nikola (NKLA), SCYNEXIS (SCYX) and Industry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolCVE:ACST Previous SymbolCVE:APO CIKN/A Webwww.acastipharma.com Phone+1-450-6864555FaxN/AEmployees32Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($0.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-10,537,760.56 Net Margins-388.46% Pretax MarginN/A Return on Equity-35.76% Return on Assets-8.25% Debt Debt-to-Equity RatioN/A Current Ratio3.44 Quick Ratio9.41 Sales & Book Value Annual SalesC$2.71 million Price / Sales6.71 Cash FlowC$0.93 per share Price / Cash Flow0.63 Book ValueC$0.86 per share Price / Book0.67Miscellaneous Outstanding Shares31,369,490Free FloatN/AMarket CapC$18.19 million OptionableNot Optionable Beta1.22 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (CVE:ACST) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acasti Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acasti Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.